호르몬 대체요법 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 투여 경로별, 질환 유형별, 지역별, 경쟁별(2020-2030년)

Hormone Replacement Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Route of Administration, By Disease Type, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,313,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,715,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,223,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

호르몬 대체요법(HRT) 세계 시장은 2024년 220억 5,000만 달러로 평가되며, 2030년에는 320억 9,000만 달러에 달할 것으로 예상되며, 연평균 6.43%의 CAGR로 성장할 것으로 예상됩니다.

이 시장은 인구통계학적 변화와 갱년기 관련 건강 문제에 대한 인식의 증가로 인해 강력한 성장세를 보이고 있습니다. 세계 인구의 고령화에 따라 폐경기를 경험하는 여성이 증가하면서 HRT 제품에 대한 수요가 급증하고 있습니다. 갱년기는 노화에 따른 자연스러운 현상이지만, 안면홍조, 식은땀, 우울감 등 갱년기 증상은 HRT를 통해 효과적으로 완화할 수 있기 때문에 인기가 높아지고 있으며, HRT의 장점과 삶의 질을 향상시키는 역할에 대한 인식이 높아지면서 채택이 더욱 확대되고 있습니다. 또한 경피 패치, 젤, 스프레이와 같은 HRT 전달 방법의 혁신은 기존의 경구용 약물을 대체할 수 있는 보다 안전하고 비침습적인 대안을 제공함으로써 호응을 얻고 있습니다. 또한, 체내에서 자연적으로 생성되는 호르몬을 반영하는 바이오 아이덴티티 호르몬의 개발은 보다 안전하고 개인화된 치료 옵션을 제공함으로써 HRT의 매력을 높이고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	220억 5,000만 달러
시장 규모 : 2030년	320억 9,000만 달러
CAGR : 2025-2030년	6.43%
급성장 부문	갑상선기능저하증
최대 시장	북미

시장 촉진요인

노인 인구 증가

주요 시장 과제

안전성 우려와 부작용

주요 시장 동향

바이오 아이덴티티 호르몬으로의 전환:

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 호르몬 대체요법 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(에스트로겐 및 프로게스테론 대체요법, HGH 대체요법, 갑상선 호르몬 대체요법, 테스토스테론 대체요법, 부갑상선호르몬 대체요법)
  • 투여 경로별(경구, 비경구, 경피, 기타)
  • 질환 종류별(갱년기장애, 갑상선기능저하증, 남성 성선기능저하증, 성장호르몬결핍증, 부갑상선기능저하증)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 호르몬 대체요법 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 호르몬 대체요법 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 호르몬 대체요법 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 호르몬 대체요법 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 호르몬 대체요법 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Abbott Laboratories
• Pfizer Inc.
• Novartis AG
• Merck KGaA
• Bayer AG
• Eli Lilly and Company
• Novo Nordisk A/S
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Hormone Replacement Therapy (HRT) Market was valued at USD 22.05 billion in 2024 and is projected to reach USD 32.09 billion by 2030, growing at a CAGR of 6.43%. This market is witnessing robust growth, driven by demographic changes and heightened awareness surrounding menopause-related health concerns. As the global population ages, more women are experiencing menopause, leading to a surge in demand for HRT products. While menopause is a natural part of aging, its associated symptoms-such as hot flashes, night sweats, and mood swings-are alleviated effectively by HRT, which is becoming increasingly popular. Awareness of its benefits and its role in enhancing quality of life is further expanding its adoption. In addition, technological innovations in HRT delivery methods, such as transdermal patches, gels, and sprays, are gaining traction, offering safer, non-invasive alternatives to traditional oral medications. Moreover, the development of bioidentical hormones, which mirror the body's naturally produced hormones, enhances the appeal of HRT by offering safer and more personalized treatment options.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 22.05 Billion
Market Size 2030	USD 32.09 Billion
CAGR 2025-2030	6.43%
Fastest Growing Segment	Hypothyroidism
Largest Market	North America

Key Market Drivers

Growth in Geriatric Population:

The aging population is a major driver for the global HRT market, as hormonal imbalances, particularly menopause, are more prevalent among older adults. By 2025, over 1 billion women globally will be experiencing menopause, with many suffering from symptoms such as hot flushes, vaginal dryness, night sweats, and weight gain. These issues are often addressed through HRT, fueling market growth. Additionally, other hormonal disorders like hypothyroidism, andropause, and adrenal insufficiency, which are more common with aging, further contribute to the demand for HRT.

Key Market Challenges

Safety Concerns and Side Effects:

Despite its popularity, HRT faces significant challenges, particularly regarding safety concerns. Prolonged use of hormone therapies has been linked to increased risks of conditions such as breast cancer, blood clots, and cardiovascular diseases. These risks, especially in women undergoing menopause treatment, have sparked debates within the medical community about the long-term safety of HRT. Furthermore, patients report a range of side effects, from mood swings and headaches to more severe issues like weight gain and nausea. Such concerns impact patient satisfaction and the broader adoption of HRT, with regulatory restrictions complicating market growth. The uncertainty surrounding long-term safety and the variety of available formulations further complicate healthcare providers' ability to recommend optimal treatments, limiting the market's expansion.

Key Market Trends

Shift Toward Bioidentical Hormones:

A growing trend within the HRT market is the shift towards bioidentical hormones. These hormones are chemically identical to those naturally produced by the body, and they are increasingly favored for their perceived safety and efficacy. Bioidentical hormones are promoted as offering a more natural alternative to synthetic hormone therapies, leading to their rising popularity. Tailored to individual needs based on hormone levels, bioidentical hormone therapy (BHT) provides a personalized solution compared to traditional hormone treatments. This trend reflects a broader shift toward personalized healthcare and is expected to further drive the market.

Key Market Players

• Abbott Laboratories
• Pfizer Inc.
• Novartis AG
• Merck KGaA
• Bayer AG
• Eli Lilly and Company
• Novo Nordisk A/S
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.

Report Scope

This report segments the Global Hormone Replacement Therapy Market as follows:

By Product:

• Estrogen & Progesterone Replacement Therapy
• HGH Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Replacement Therapy
• Parathyroid Hormone Replacement

By Route of Administration:

• Oral
• Parenteral
• Transdermal
• Others

By Disease Type:

• Menopause
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency
• Hypoparathyroidism

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of the leading players in the global HRT market, focusing on their market share, strategies, and innovations. Customization options for this report are also available, allowing companies to access further details about additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hormone Replacement Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Estrogen & Progesterone Replacement Therapy, HGH Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, Parathyroid Hormone Replacement)
  • 5.2.2. By Route of Administration (Oral, Parenteral, Transdermal, Others)
  • 5.2.3. By Disease Type (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Hypoparathyroidism)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Hormone Replacement Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Disease Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hormone Replacement Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Disease Type
  • 6.3.2. Mexico Hormone Replacement Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Disease Type
  • 6.3.3. Canada Hormone Replacement Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Disease Type

7. Europe Hormone Replacement Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Disease Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Hormone Replacement Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Disease Type
  • 7.3.2. Germany Hormone Replacement Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Disease Type
  • 7.3.3. United Kingdom Hormone Replacement Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Disease Type
  • 7.3.4. Italy Hormone Replacement Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Disease Type
  • 7.3.5. Spain Hormone Replacement Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Disease Type

8. Asia-Pacific Hormone Replacement Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Disease Type
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Hormone Replacement Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Disease Type
  • 8.3.2. India Hormone Replacement Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Disease Type
  • 8.3.3. South Korea Hormone Replacement Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Disease Type
  • 8.3.4. Japan Hormone Replacement Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Disease Type
  • 8.3.5. Australia Hormone Replacement Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Disease Type

9. South America Hormone Replacement Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By Disease Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Hormone Replacement Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Disease Type
  • 9.3.2. Argentina Hormone Replacement Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Disease Type
  • 9.3.3. Colombia Hormone Replacement Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Disease Type

10. Middle East and Africa Hormone Replacement Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By Disease Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Hormone Replacement Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Disease Type
  • 10.3.2. Saudi Arabia Hormone Replacement Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Disease Type
  • 10.3.3. UAE Hormone Replacement Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Novartis AG
• 14.4. Merck KGaA
• 14.5. Bayer AG
• 14.6. Eli Lilly and Company
• 14.7. Novo Nordisk A/S
• 14.8. F. Hoffmann-La Roche Ltd.
• 14.9. Amgen Inc.
• 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료